These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21174613)

  • 1. Capecitabine and hand-foot syndrome.
    Saif MW
    Expert Opin Drug Saf; 2011 Mar; 10(2):159-69. PubMed ID: 21174613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
    Do JE; Kim YC
    Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report.
    Lee SD; Kim HJ; Hwang SJ; Kim YJ; Nam SH; Kim BS
    Korean J Intern Med; 2007 Jun; 22(2):109-12. PubMed ID: 17616027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acral and palmo-plantar hyperpigmentation in a patient with disseminated hepatocellular carcinoma.
    Goyal R; Chalamalasetty SB; Madan K; Paul SB; Arora R; Safaya R; Acharya SK
    Indian J Gastroenterol; 2007; 26(6):292-3. PubMed ID: 18431015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
    Saif MW; Elfiky A; Diasio R
    Clin Colorectal Cancer; 2006 Sep; 6(3):219-23. PubMed ID: 17026792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hand-foot syndrome with capecitabine therapy].
    Marini A; Hengge UR
    Hautarzt; 2007 Jun; 58(6):532-6. PubMed ID: 16897045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
    Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
    Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequency of hand foot syndrome with capecitabine.
    Kamil M; Haron M; Yosuff N; Khalid I; Azman N
    J Coll Physicians Surg Pak; 2010 Jun; 20(6):421-2. PubMed ID: 20642979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
    Kang YK; Lee SS; Yoon DH; Lee SY; Chun YJ; Kim MS; Ryu MH; Chang HM; Lee JL; Kim TW
    J Clin Oncol; 2010 Aug; 28(24):3824-9. PubMed ID: 20625131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
    Risum S; Langer SW
    Ugeskr Laeger; 2003 Aug; 165(33):3161-2. PubMed ID: 12968412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient.
    Tavares-Bello R
    J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1434-5. PubMed ID: 17958867
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
    Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
    Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A woman with palmar and plantar hyperpigmentation].
    van Tienhoven G; Wilmink JW
    Ned Tijdschr Geneeskd; 2011; 155(45):A4100. PubMed ID: 22085578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine.
    Villalón G; Martín JM; Pinazo MI; Calduch L; Alonso V; Jordá E
    Am J Clin Dermatol; 2009; 10(4):261-3. PubMed ID: 19489659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding.
    Latif S; Fraga G; Gadzia J
    J Drugs Dermatol; 2010 Mar; 9(3):268-70. PubMed ID: 20232590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of capecitabine-induced hand-foot syndrome by local phytotherapy].
    Kern E; Schmidinger M; Locker GJ; Kopp B
    Wien Med Wochenschr; 2007; 157(13-14):337-42. PubMed ID: 17704983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical henna for capecitabine induced hand-foot syndrome.
    Yucel I; Guzin G
    Invest New Drugs; 2008 Apr; 26(2):189-92. PubMed ID: 17885735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer.
    Vickers MM; Easaw JC
    J Gastrointest Cancer; 2008; 39(1-4):141-3. PubMed ID: 19440857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of hand-foot syndrome induced by capecitabine.
    Gressett SM; Stanford BL; Hardwicke F
    J Oncol Pharm Pract; 2006 Sep; 12(3):131-41. PubMed ID: 17022868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
    Lassere Y; Hoff P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S31-40. PubMed ID: 15341880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.